Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug autoinjector vs prefilled syringe pharmacokinetics in healthy volunteers
NCT07056309Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of remternetug (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 85 days, Area Under the Concentration Versus Time Curve from Zero to Time t at 85 days and 1 more. Started Jun 2025; status: completed.
02
Drugs
remternetug
Beyond the preview
Go deeper on NCT07056309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056309.